As quoted in the press release:
Tetra’s development and manufacturing partner, PS Innovations, will be seeking CE Marking for Tetra’s Rx Princeps Inhalation Device, which is used in conjunction with a dried loose cannabis, such as Rx Princeps, to provide relief for advanced cancer pain and non-cancer pain patients.
Rx Princeps is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps is composed of the same medical cannabis blend used to produce PPP001, the lead product in Tetra’s pipeline of five cannabinoid-based prescription drugs seeking Health Canada and FDA approval in Canada and the United States.
“We know that more than half the people who consume cannabis choose to smoke it,” said Mr. Fortier. “This first step into Europe with a strong partner like PS Innovations solidifies our strategic focus on global expansion and potentially offers the European medical community and their patients the most innovative therapeutic options.”